In February 2023, it was announced that the Basque Office for Health Technology Assessment (OSTEBA) initiated several HTAs, including the following evaluations in the e-health, radiology, nephrology and urology, cardiovascular, IVD, obstetrics and gynecology, diagnostic imaging, radiotherapy, neurovascular, ENT, interventional radiology, surgical procedures, and some other fields. Some examples can be found below:
- Clinical efficacy and cost-effectiveness of incorporating artificial intelligence into the breast cancer screening program;
- Telemonitoring and computerized management of patients on home dialysis and rehabilitation activities;
- Cardiovascular monitoring system that uses photoplethysmography;
- Molecular diagnostic test for multidrug-resistant microorganisms;
- Intrasaccular device for endovascular treatment of brain aneurysms;
- HIFU – High-intensity focused ultrasound;
- Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of pediatric patients with peritoneal carcinomatosis;
- Robotic system for the preparation of oncological medication.
The full details in Spanish can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.